Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

We are a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases.

We aspire to develop best-in-class medicines across multiple therapeutic modalities using PRISM TM, our proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, we are targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.

Innovative Platform

Foundation of Neurology Programs

Clinical Development Expertise

GMP Manufacturing

 

Investor Relations

Recent News

May 10, 2022

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. , May 10, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno , MD, MBA, President and Chief Executive

Recent News

May 10, 2022

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. , May 10, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno , MD, MBA, President and Chief Executive
Recent News and Events

Data Provided by Refinitiv. Minimum 15 minutes delayed.